FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Efficacy and Safety of Budesonide Orodispersible Tablets for Eosinophilic Esophagitis up to 3 Years: An Open-Label Extension Study. PMID 39694205 · Clin Gastroenterol Hepatol · 2025-Nov 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial. PMID 39174409 · Eur Urol · 2025-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial. PMID 40474841 · Br J Surg · 2025-May-31 The study is a randomized phase III trial in oncology with drug interventions, but the abstract does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier curves, or HR). The efficacy endpoints mentioned are TIL-IMP manufacture failure rates and response rates (objective response), which are categorical outcomes, not time-to-event endpoints. Therefore, it does not meet the requirement for a time-to-event efficacy endpoint for inclusion in the Kaplan-Meier digitization cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| WITHDRAWN: Personalized bevacizumab dosing in metastatic colorectal cancer: Statistical considerations for a phase III randomized trial. PMID 40451669 · Dig Liver Dis · 2025-May-31 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Clinical efficacy of Shaomazhijing granules in the treatment of Tourette's syndrome: a randomized controlled trial. PMID 40450353 · Hereditas · 2025-May-31 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The Design of a Patient-Centered Hierarchal Composite Outcome for a Multi-Center Randomized Controlled Trial in Metastatic Bone Disease. PMID 40558261 · Curr Oncol · 2025-May-30 The record describes the design and outcome development for a randomized controlled trial (PERFORM), but it does not report the results of a completed Phase III or Phase II/III trial. The primary outcomes identified are composite and include mortality, physical function, and days at home, but there are no results reported for these endpoints (no KM curves, HRs, etc.). The study is explicitly a protocol/design paper for an ongoing trial, not an original result report. Furthermore, the intervention is surgical (reconstruction vs. fixation), not a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS). PMID 40448185 · Trials · 2025-May-30 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. PMID 40447307 · BMJ · 2025-May-30 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The efficacy of combined lateral and anterior quadratus lumborum blocks in postoperative pain management following pelvic tumor resection: a randomized controlled trial. PMID 40442734 · J Orthop Surg Res · 2025-May-29 The study is a randomized controlled trial in oncology patients (pelvic tumor resection) but it is not a drug-containing intervention trial for a systemic oncology therapy. The intervention is a regional anesthetic nerve block (Quadratus lumborum block) for postoperative pain management. There is no specified trial phase (Phase III/IIIb or Phase II/III), and the primary endpoints are postoperative pain scores, opioid consumption, and recovery quality—none of which are the required time-to-event efficacy endpoints (OS, PFS, etc.) with Kaplan-Meier or HR analysis for an oncology drug. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant chemotherapy with or without PD-1/PD-L1 inhibitors in resectable esophageal squamous cell carcinoma: a meta-analysis based on randomized controlled trials. PMID 40442612 · BMC Gastroenterol · 2025-May-29 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A pragmatic, multicenter, randomized trial comparing morning versus evening dosing of adjuvant endocrine therapy (REaCT-CHRONO Study). PMID 40442096 · NPJ Breast Cancer · 2025-May-29 The study is a randomized, drug-intervention trial in oncology (breast cancer) reporting original primary results. However, it is excluded because it does not report a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR) as a primary or key secondary outcome. The primary endpoint is toxicity/tolerability (FACT-ES score), and secondary endpoints are toxicity, QoL, and adherence. Furthermore, the phase is not explicitly established as Phase III or IIIb; it is described as a 'pragmatic, multicenter, randomized trial' without a specified phase. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis. PMID 40174237 · N Engl J Med · 2025-May-29 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. PMID 40167274 · N Engl J Med · 2025-May-29 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Robot-assisted versus video-assisted thoracoscopic thymectomy for stage I-II thymic epithelial tumour: a protocol for the first multicentre, randomised controlled clinical trial. PMID 40441770 · BMJ Open · 2025-May-28 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of a house dust mites allergoid in patients with allergic rhinitis-PROACAROS study: protocol for a randomized controlled trial. PMID 40437636 · Trials · 2025-May-28 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Hepatitis B: Protocol for a Phase 3 Randomized Trial. PMID 40385939 · J Clin Transl Hepatol · 2025-May-28 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Interventional arterial chemotherapy versus sorafenib for advanced hepatocellular carcinoma in China: a health economic evaluation of open-label, randomised, phase 3 study. PMID 40436447 · BMJ Open · 2025-May-27 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation. PMID 40421698 · Cochrane Database Syst Rev · 2025-May-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy. PMID 40398971 · J Am Coll Cardiol · 2025-May-27 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Modeling Disease Progression and Placebo Response in Huntington Disease: Insights From Enroll-HD and GENERATION HD1 Cohorts. PMID 40315394 · Neurology · 2025-May-27 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Metformin for Knee Osteoarthritis in Patients With Overweight or Obesity: A Randomized Clinical Trial. PMID 40274279 · JAMA · 2025-May-27 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Prothrombin Complex Concentrate vs Frozen Plasma for Coagulopathic Bleeding in Cardiac Surgery: The FARES-II Multicenter Randomized Clinical Trial. PMID 40156829 · JAMA · 2025-May-27 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis With Cardiomyopathy. PMID 40099774 · J Am Coll Cardiol · 2025-May-27 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study. PMID 40085955 · Blood Adv · 2025-May-27 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non-low-risk AML. PMID 40048742 · Blood Adv · 2025-May-27 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study. PMID 39908481 · Blood Adv · 2025-May-27 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with treatment-refractory OUD: A randomized, double-blind, placebo-controlled clinical trial protocol. PMID 40502777 · Res Sq · 2025-May-26 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Accelerometer measurement error in a randomized physical activity intervention trial in breast cancer survivors was nondifferential but attenuated the intervention effect. PMID 40420153 · Int J Behav Nutr Phys Act · 2025-May-26 This is an original randomized trial report in breast cancer survivors. However, it is not a Phase III/IIIb or Phase II/III trial of a drug-containing intervention, and its primary efficacy endpoint (change in physical activity energy expenditure) is not a time-to-event outcome like OS, PFS, or DFS, nor does it involve Kaplan-Meier analysis or hazard ratios. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of intravenous lidocaine on postoperative fatigue syndrome in patients undergoing laparoscopic radical colorectal cancer surgery: a randomized clinical trial. PMID 40415064 · Sci Rep · 2025-May-25 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of combining tislelizumab with capecitabine compared to capecitabine alone in the adjuvant treatment of biliary tract cancers: rationale and protocol design for a randomized clinical trial. PMID 40414848 · BMC Cancer · 2025-May-25 The record is a protocol for a randomized trial, not an original result report of a completed trial. The deterministic review correctly identified it as a 'protocol_without_results', but the metadata's phase is unclear and it is not an original result report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Prostate cancer-Exercise and Metformin randomised controlled feasibility Trial (Pre-EMpT) in men following active surveillance, radical prostatectomy and radiotherapy. PMID 40413550 · Pilot Feasibility Stud · 2025-May-24 The study is a Phase II feasibility trial (not definitive Phase III/IIIb or Phase II/III) and lacks a primary or key secondary time-to-event efficacy endpoint; it focuses on feasibility outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| HSK21542 in patients with postoperative pain: two phase 3, multicentre, double-blind, randomized, controlled trials. PMID 40413233 · Nat Commun · 2025-May-24 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Major depressive disorder in children and adolescents is associated with reduced hair cortisol and anandamide (AEA): cross-sectional and longitudinal evidence from a large randomized clinical trial. PMID 40413177 · Transl Psychiatry · 2025-May-24 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| An adaptive multiarm randomised trial of biomedical and psychosocial interventions to improve convalescence following severe acute malnutrition in sub-Saharan Africa: Co-SAM trial protocol. PMID 40413053 · BMJ Open · 2025-May-24 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Tislelizumab as adjuvant therapy following endoscopic surgery for resectable recurrent nasopharyngeal carcinoma: a randomized clinical trial. PMID 40413023 · J Immunother Cancer · 2025-May-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A Proof-of-Concept Clinical Trial Design for Evolutionary Guided Precision Medicine for Cancer. PMID 40661270 · medRxiv · 2025-May-23 This is a proof-of-concept clinical trial design and simulation study (a protocol/methodological paper) for a novel precision medicine strategy. It does not report results from an actual Phase III or definitive randomized trial with a drug intervention and a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of TROP-2-Targeting Antibody-Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient Data. PMID 40507234 · Cancers (Basel) · 2025-May-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Early mobilization in postoperative glioma patients real world impact on recovery and long term prognosis. PMID 40410289 · Sci Rep · 2025-May-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Development and Pilot Testing of an Addiction Clinic-Based Pre-Exposure Prophylaxis Uptake and Adherence Intervention for Women with Substance Use Disorders: Protocol for a Pilot Randomized Trial. PMID 40409752 · JMIR Res Protoc · 2025-May-23 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Treating Lower Phantom Limb Pain in the Postoperative Acute Care Setting Using Virtual Reality: Protocol for a 4-Phase Development and Feasibility Trial. PMID 40409745 · JMIR Res Protoc · 2025-May-23 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: results from two phase III trials in patients with moderate-to-severe atopic dermatitis. PMID 39680511 · Clin Exp Dermatol · 2025-May-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Staged Turnbull-Cutait pull-through anastomosis comparing with direct anastomosis plus prophylactic ileostomy in the treatment of low rectal cancer after internal sphincter resection (STAR-TAR): study protocol for a randomized controlled trial. PMID 40405283 · Trials · 2025-May-22 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Phase 2 study design and analysis approach for BBT-877: an autotaxin inhibitor targeting idiopathic pulmonary fibrosis. PMID 40404183 · BMJ Open Respir Res · 2025-May-22 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Pancreatic resection with perioperative drug repurposing of propranolol and etodolac - the phase II randomized controlled PROSPER trial. PMID 40402347 · Langenbecks Arch Surg · 2025-May-22 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Rapid Reduction of Pro-Inflammatory Cytokines with an Oral Topical Composition Comprising Olive Oil, Trimethylglycine and Xylitol: A Randomized Double-Blind Controlled Trial. PMID 40430061 · Int J Mol Sci · 2025-May-21 The study is a randomized, double-blind, controlled trial in human subjects with an original result report. However, it is not an oncology study (investigates periodontitis and obesity), does not involve a drug intervention (tests a topical composition of olive oil, trimethylglycine, and xylitol in toothpaste), and does not have a primary time-to-event efficacy endpoint (primary outcomes are salivary cytokine levels, not OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Associations of pretreatment emotional distress with adherence to therapy for patients with locally advanced rectal cancer: a post hoc analysis of the Chinese FOWARC phase 3 randomized clinical trial. PMID 40399932 · BMC Med · 2025-May-21 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Study protocol of short versus long-term levetiracetam in brain tumors (LIBRA): a phase 3 randomized controlled trial. PMID 40399827 · BMC Cancer · 2025-May-21 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Psychometric validation of the EORTC QLQ-OES18 in patients with advanced or metastatic esophageal squamous cell carcinoma. PMID 40397297 · J Patient Rep Outcomes · 2025-May-21 The study is a psychometric validation of a patient-reported outcome measure (QoL) within a Phase III randomized trial; it does not report primary or key secondary time-to-event efficacy outcomes (OS, PFS, etc.) with Kaplan-Meier or HR. Therefore, it is excluded. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Vaccines for preventing infections in adults with haematological malignancies. PMID 40396505 · Cochrane Database Syst Rev · 2025-May-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A review of mirvetuximab soravtansine-gynx in folate receptor alpha-expressing platinum-resistant ovarian cancer. PMID 40126684 · Am J Health Syst Pharm · 2025-May-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |